Dr. reddy's laboratories announces the launch of febuxostat tablets in the u.s. market

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced the launch of febuxostat tablets, a therapeutic equivalent generic version of uloric (febuxostat) tablets approved by the u.s. food and drug administration (usfda). the uloric brand and generic had u.s. sales of approximately $108 million mat for the most recent twelve months
RDY Ratings Summary
RDY Quant Ranking